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Various types of zinc (Zn) complexes have been developed as promising antidiabetic agents in recent
years. However, the pharmacological action of Zn complex is not elucidated because the biodistribution
of the complex in a living organism has not been studied. Nuclear medicine imaging is superior tech-
nology for the noninvasive analysis of the temporal distribution of drug candidates in living organisms.
Gamma-ray emission imaging (GREI), which was developed by our laboratory as a novel molecular
imaging modality, was adopted to visualize various γ-ray–emitting radionuclides that are not detected by
conventional imaging techniques such as positron emission tomography and single-photon emission
computed tomography. Therefore, we applied GREI to a biodistribution assay of Zn complexes. In the
present study, 65Zn was produced in the natCu(p,n) reaction in an azimuthal varying ﬁeld cyclotron for
the GREI experiment. The distribution was then noninvasively visualized using GREI after the in-
travenous administration of a 65Zn-labeled di(1-oxy-2-pyridinethiolato)zinc [Zn(opt)2], ZnCl2, and di(L-
histidinato)zinc. The GREI images were validated using conventional invasive assays. This novel study
showed that GREI is a powerful tool for the biodistribution analysis of antidiabetic Zn complexes in a
living organism. In addition, accumulation of 65Zn in the cardiac blood pool was observed for [Zn(opt)2],
which exhibits potent antidiabetic activity. These results suggest that the slow elimination of Zn from the
blood is correlated to the antidiabetic activity of [Zn(opt)2].
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Medicinal inorganic chemistry is a discipline in which metal
complexes are used in therapeutic and diagnostic medicine [1–3].B.V. This is an open access article u
a-ray emission imaging; PET,
emission computed tomo-
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edicine, Dentistry, and Phar-
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ts, and Nutrition Faculty of
-7-2 Minatojima-nakamachi,
mistry, Daiichi University of
815-8511, Japan.The zinc (Zn) complexes are promising metallodrugs for the
treatment of type 2 diabetes mellitus [4–5]. In recent years, several
Zn complexes have been discovered that have potent antidiabetic
activity in experimental diabetic animals [5–7]. For example, a
novel Zn complex showed potent hypoglycemic activity at a dose
lower than the clinical dose of zinc acetate used to treat Wilson's
disease [7]. It is presumed that the Zn atom is the component of
the complex responsible for its hypoglycemic activity since ligands
such as low-molecular-weight organic compounds are generally
inactive. The complexation of Zn with a ligand improves its gas-
trointestinal absorption, enabling its efﬁcient delivery to target
tissues [7–9]. The coordination mode of the Zn complex also in-
ﬂuences its pattern of tissue distribution [9,10]. However, the
pharmacological action of Zn complexes is not fully elucidated
because their biodistribution in vivo has not been extensively
studied. Therefore, the development of noninvasive methods fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the discovery of safe and efﬁcacious Zn complexes for treatment of
type 2 diabetes.
The nuclear medicine imaging technique is useful in early drug
development for analyzing the biokinetics of drug candidates in
experimental animals and humans (i.e., clinical microdose studies)
[11,12]. Positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) are widely used to non-
invasively visualize the movements of radionuclide-labeled mo-
lecules [13,14]. However, PET is limited to determine 511 keV
γ-rays that originate from positron-emitting radionuclide while
PET is more sensitive and accurate than other molecular imaging
techniques. In SPECT imaging, γ-rays with low energy
(o300 keV) emitted from the radionuclide are detected. There-
fore, these conventional apparatuses are not suitable for the
measurement and visualization of the in vivo behavior of the Zn
complex because 65Zn chosen as a radionuclide for the labeling
emits γ-ray with high energy of 1116 keV.
On the other hand, the gamma-ray emission imaging (GREI)
apparatus developed in our laboratory enables the spectroscopic
imaging of wide energy-range γ-rays (200–2000 keV) by using a
semiconductor Compton camera system [15]. The in vivo imaging
of different γ-ray–emitting radionuclides, such as 65ZnCl2, 85SrCl2,
iodinated (131I) methylnorcholesterol and others, was achieved
using GREI [15–17]. Successful demonstrations of the multiple
molecular imaging inspired us to apply GREI to the biodistribution
analysis of the Zn complex in a living organism. This study was the
ﬁrst to noninvasively investigate the kinetic behaviors of the di(1-
oxy-2-pyridinethiolato)zinc complex ([Zn(opt)2]), which has po-
tent antidiabetic activity, using GREI after an intravenous admin-
istration of 65Zn-labeled [Zn(opt)2]. The distribution was compared
to those of ZnCl2 and the di(L-histidinato)zinc complex
([Zn(His)2]), which does not exhibit antidiabetic activity.2. Experimental
2.1. Animals
Ten-week-old male C57BL/6J mice were purchased from CLEA
Japan, Inc. All animals were housed under a 12-h light/dark cycle
in a temperature-controlled animal room and were allowed free
access to food and tap water. All animal experiments were ap-
proved by the Ethics Committee on Animal Care and Use of RIKEN
and were performed in accordance with the Guide for the Care and
Use of Laboratory Animals.
2.2. Probe preparation
The 65Zn nuclide was produced in the natCu(p,n) reaction (nat:
natural isotopic abundance) in a RIKEN azimuthal varying ﬁeldFig. 1. Proposed coordination structures of the di(1-oxy-2-pyridinethiolato)Zcyclotron. A metallic copper foil (chemical purity: 99.99%)
220 mg/cm2 thick was irradiated by a 14-MeV proton beam with
an intensity of 15 mA. After the irradiation, 65Zn was chemically
separated from the Cu target by an anion-exchange method.
Radionuclide purity499% was determined by the γ-ray
spectrometry using a calibrated Ge detector. The speciﬁc
radioactivity40.2 GBq/g was estimated by inductively coupled
plasma mass spectrometry for a control sample that was treated
with the same chemical process as the irradiated Cu target.
[Zn(opt)2] and [Zn(His)2] were prepared as previously de-
scribed [8,18], and the complexes were determined by elemental
analyses and infrared spectra. Their predicted coordination struc-
tures are shown in Fig. 1 [19,20].
Puriﬁed 65Zn dissolved in 30 μL of saline (Otsuka Pharmaceu-
tical Co. Ltd.) and [Zn(opt)2] dissolved in 70 μL of dimethyl sulf-
oxide (DMSO; Wako Pure Chemical Industries Ltd.) or [Zn(His)2]
dissolved in 70 μL of saline were stirred at room temperature over
night to exchange cold Zn and 65Zn [7,9,10]. The 65ZnCl2 solution, a
mixture of 65Zn dissolved in 30 μL of saline and ZnCl2 dissolved in
70 μL of DMSO, was prepared immediately prior to administration.
The solutions were prepared to contain 10 mg Zn/mL as well as
10 MBq/mL or 2.5 MBq/mL for the GREI experiment or biodis-
tribution analysis, respectively.2.3. GREI experiment
Eleven-week-old male C57BL/6J mice were intravenously ad-
ministered a single dose of 65Zn-labeled [Zn(opt)2] ([65Zn(opt)2]),
65Zn-labeled ZnCl2 (65ZnCl2), or 65Zn-labeled [Zn(His)2]
([65Zn(His)2]) via the tail vein at 1.0 mg Zn/kg of body weight. Each
mouse was ﬁxed on a board and placed just under the imaging
head. Fifteen minutes after the injection, the GREI experiments
were carried out under isoﬂurane anesthesia for 8 h. The acquired
data were recorded in list mode with real-, and live-time in-
formation. The distribution images were reconstructed from the
acquired data by the adoption of the image-reconstruction
methods as previously described [15].2.4. Biodistribution analysis
Eleven-week-old male C57BL/6J mice were divided into
[65Zn(opt)2]-, 65ZnCl2-, and [65Zn(His)2]-treated groups, and the
65Zn-labeled compounds were intravenously administered at a dose
of 1.0 mg Zn/kg of body weight. Four hours after the single in-
travenous administration, the mice were sacriﬁced under isoﬂurane
anesthesia. Blood was collected, and the organs of interest (heart,
pancreas, liver, kidney, stomach) were removed. Their radio-
activities due to 65Zn were measured using a calibrated Ge detector.n and di(L-histidinato)Zn complexes. Charges are omitted for simplicity.
Fig. 2. Distribution images of 65Zn in C57BL/6J mice after the administration of the 65Zn-labeled Zn compounds ([65Zn(opt)2] (O), 65ZnCl2 (C), or [65Zn(His)2] (H)) re-
constructed every 2 h. The arrows indicate the characteristic accumulation of 65Zn.
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3.1. Visualization of 65Zn-labeled Zn complexes in the whole body by
GREI
The distribution images of 65Zn were reconstructed every 2 h
after the administration of [65Zn(opt)2], 65ZnCl2, or [65Zn(His)2]
(Fig. 2). The arrows indicate the characteristic accumulation of
65Zn. High accumulation of all compounds was observed in the
liver. Moreover, a different distribution of 65Zn among the studied
Zn compounds was obtained in the distribution images: in the
heart, high accumulation of [65Zn(opt)2] was noted, whereas little
accumulation was observed for 65ZnCl2 and [65Zn(His)2].
The regions of interest were drawn around the heart and liver
and the numerical values of the distributions was calculated by
integrating the pixel values inside them to compare the values inFig. 3. Image intensities of the 65Zn accumulated in the liver (a) and heart (b) extractthe heart and liver of each mouse (Fig. 3). Image intensity gra-
dients in such organs for each compound were maintained for 8 h
and indicated that 65Zn accumulation for [65Zn(opt)2] was much
higher in the heart and lower in the liver than those for other
studied compounds.
3.2. Biodistribution of 65Zn
The radioactivities due to 65Zn in the resected organs and blood
were determined 4 h after the administration of [65Zn(opt)2],
65ZnCl2, or [65Zn(His)2] (Fig. 4). As shown in Fig. 4a, the uptake of
65Zn in the liver was the highest, whereas the uptake rate (ex-
pressed as percent injected dose [%ID]) in the liver was at least
twice as high as those in other organs for all compounds. The
uptake rate of 65Zn in the liver, pancreas, and kidney of
[65Zn(opt)2]-treated mice were reduced compared with the uptakeed from each time ﬂame of the images for [65Zn(opt)2], 65ZnCl2, and [65Zn(His)2].
Fig. 4. The uptake rate of 65Zn in each tissue (a) and in the blood (b) at 4 h after an intravenous administration of di(1-oxy-2-pyridinethiolato)Zn ([65Zn(opt)2]), 65ZnCl2, or di
(L-histidinato)Zn ([65Zn(His)2]). Data are expressed as mean values7SD for four mice. For the statistical evaluation, one-way analysis of variance with Bonferroni's test was
used. *Po0.05, **Po0.01, ***Po0.001 versus [65Zn(opt)2]. %ID, percent injected dose.
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the other hand, the uptake rate in the heart tissue of
[65Zn(opt)2]-treated mice was signiﬁcantly higher than those of
65ZnCl2- and [65Zn(His)2]-treated mice. In addition, the con-
centration of 65Zn (expressed as %ID/g tissue) in blood samples as
[65Zn(opt)2] was much higher than that as 65ZnCl2 or [65Zn(His)2]
(Fig. 4b).4. Discussion
Biodistribution analyses of drug candidates enable the evalua-
tion and prediction of their biological effects. For the assessment
of the Zn complexes, tissue distribution patterns of exogenous Zn
have been invasively analyzed by the determination of 65Zn
radioactivity in each tissue removed from the experimental ani-
mals after the administration of the 65Zn-labaled Zn complex
[7,9,10]. In general, the conventional method requires much time,
high cost, and signiﬁcant labor to assess drug candidate distribu-
tion. On the other hand, the molecular imaging technique enables
a noninvasive and temporary study in the same living animals,
decreases its statistical variance, and reduces the number of sub-
jects. Therefore, we developed a noninvasive method for analyzing
the distribution of 65Zn-labeled Zn complexes in live mice using
GREI. The conventional invasive assays were also performed to
validate the GREI images.
In GREI experiments, we were the ﬁrst to successfully visualize
the difference in distribution among the 65Zn-labeled compounds
after their intravenous injection (Fig. 2). The distribution images of
65Zn for all compounds in the liver and heart were in agreement
with the results of the invasive assay (Figs. 3 and 4). The accu-
mulation of 65Zn increased in the liver of 65ZnCl2- and
[65Zn(His)2]-treated mice, while the image intensities in the
[65Zn(opt)2]-treated mouse was low. This tendency was also ob-
served in the uptake rate of 65Zn in the liver by the invasive assay.
In addition, the accumulation of 65Zn in the heart of
[65Zn(opt)2]-treated mouse observed in the GREI image corres-
ponds to the results that both 65Zn blood concentration and 65Zn
uptake into the heart tissue in [65Zn(opt)2]-treated mice were
higher than those in 65ZnCl2-, [65Zn(His)2]-treated mice. It is wellknown that the values of the thoracic pool (blood volume in the
heart and lungs) amount to about 30% of the total circulatory
blood volume [21]. The accumulation in the heart would be mainly
derived from the enormously high concentration of 65Zn in the
blood of [65Zn(opt)2]-treated mice because the uptake rates of 65Zn
in the heart tissue were low. These results suggest that the dis-
tribution images of 65Zn reﬂected the biodistributions determined
by the invasive method.
Interestingly, the characteristic accumulation of 65Zn was ob-
served in the heart of [65Zn(opt)2]-treated mouse. The invasive
assay exhibited that the accumulation was mainly derived from
the radioactivity of 65Zn in the cardiac blood pool. It was reported
that a relatively long retention time of 65Zn in the blood leads to a
sustained release of Zn, which may be an important factor in the
exertion of its antidiabetic activity [7,10]. The presented results
suggested that the slow elimination of Zn from blood is related to
the high antidiabetic activity of [Zn(opt)2].
In conclusion, here we successfully demonstrated that GREI
enables the noninvasive analysis of 65Zn distribution for
[65Zn(opt)2], 65ZnCl2, and [65Zn(His)2] in intact live mice as well as
the visualization of the differences in 65Zn distribution among
these compounds. The accumulation of 65Zn in the cardiac blood
pool was observed for [Zn(opt)2] as an antidiabetic drug candidate
and suggested that the slow elimination of Zn from the blood may
be an important factor related to its antidiabetic activity. We are
currently investigating the correlation between the distribution
pattern of the Zn complex and its antidiabetic activity, in addition
to developing the GREI system to realize faster and more quanti-
tative imaging analyses.Acknowledgment
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